E-viri
PDF
Recenzirano
Odprti dostop
-
Agnelli, Giancarlo; Becattini, Cecilia; Meyer, Guy; Muñoz, Andres; Huisman, Menno V; Connors, Jean M; Cohen, Alexander; Bauersachs, Rupert; Brenner, Benjamin; Torbicki, Adam; Sueiro, Maria R; Lambert, Catherine; Gussoni, Gualberto; Campanini, Mauro; Fontanella, Andrea; Vescovo, Giorgio; Verso, Melina
The New England journal of medicine, 04/2020, Letnik: 382, Številka: 17Journal Article
In a randomized trial, oral apixaban was noninferior to a low-molecular-weight heparin, dalteparin, in preventing recurrent venous thromboembolism at 6 months in patients with cancer. The use of apixaban was not associated with a higher risk of major bleeding than dalteparin, even in patients with gastrointestinal cancer.
